Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × Cholangiocarcinoma × futibatinib × Clear all

Phase

Status

Recruiting 1 Enrolling by invitation 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 1 Cholangiocarcinoma 1

Interventions

futibatinib 1 camrelizumab 1 anlotinib 1 S 1 (combination) 1 Liver Transplantation 1 Fulvestrant 1 Chemoradiotherapy 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡